$DFTX News
Last published 1d ago
- 1d agoDFTXSTIFEL 2026 HEALTHCARE CONFERENCE - DEFINIUM THERAPEUTICS INCEarnings Call Transcriptsall right um thanks everybody for joining um thanks especially to max for joining uh happy to be here with dan carlin chief medical officer of definium therapeutics i'm sure folks know the story well but super topical ti
- 2d agoDFTXDefinium Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoDFTXDefinium Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsBusiness WireNEW YORK--(BUSINESS WIRE)-- #GAD--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended September 30, 2026, and recent highlights. The Company also repo ...
- 2d agoDFTXDefinium Therapeutics Q3 2026 Earnings Conference Call - DEFINIUM THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, and welcome to the Definium Therapeutics Third Quarter 2026 Financial Results and Business Updates webcast. Currently, all participants are in a listen-only mode. This webcast is live on the Investor and
- 1w agoDFTXDefinium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026Business WireDefinium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders,
- 2w agoDFTXDefinium Therapeutics Announces New Employee Inducement GrantsBusiness WireDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of
- 4w agoDFTXDefinium Therapeutics Announces New Employee Inducement GrantsBusiness WireDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric
- 1mo agoDFTXDefinium Therapeutics Announces New Employee Inducement GrantsBusiness WireDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of
- 1mo agoDFTXTD COWEN 6TH ANNUAL NOVEL MECHANISMS IN NEUROPSYCHIATRY SUMMIT - DEFINIUM THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. Thanks for joining us for the Definium Therapeutics Fireside Chat at the 6th Annual Novel Mechanisms of Neuropsychiatry TD Cowan Summit. With us from Definuum, we have Chief Medical Officer Dan Ca
- 1mo agoDFTXTD COWEN 6TH ANNUAL NOVEL MECHANISMS IN NEUROPSYCHIATRY SUMMIT - DEFINIUM THERAPEUTICS INCEarnings Call TranscriptsGood morning, everyone. Thanks for joining us for the Definium Therapeutics Fireside Chat at the 6th Annual Novel Mechanisms of Neuropsychiatry TD Cowan Summit. With us from Definuum, we have Chief Medical Officer Dan Ca
- 1mo agoDFTXPhase 3 Panorama Topline Results: DT120 ODT in Generalized Anxiety Disorder - DEFINIUM THERAPEUTICS INCEarnings Call TranscriptsWelcome to the Delphinium Therapeutics Phase 3 Panorama Topline Results Call. Today's call is being recorded. At this time, all participants are in a listen-only mode. Following the prepared remarks, we will open the cal
- 1mo agoDFTXPHASE 3 PANORAMA TOPLINE RESULTS: DT120 ODT IN GENERALIZED ANXIETY DISORDER - DEFINIUM THERAPEUTICS INCEarnings Call TranscriptsWelcome to the Delphinium Therapeutics Phase 3 Panorama Topline Results Call. Today's call is being recorded. At this time, all participants are in a listen-only mode. Following the prepared remarks, we will open the cal
- 1mo agoDFTXDefinium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety DisorderBusiness WireStudy met primary and all key secondary efficacy endpoints; Panorama is the second positive Phase 3 trial for DT120 ODT in GAD and the third positive Phase 3 trial for DT120 ODT Participants receiving DT120 ODT 100
- 1mo agoDFTXDefinium Therapeutics Announces New Employee Inducement GrantsBusiness WireDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of
- 1mo agoDFTXDefinium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026Business WireCompany to host webcast tomorrow at 8:00 a.m. EDT Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics
- 2mo agoDFTXDefinium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026Business WireEmerge Phase 3 study podium poster to be featured in "Latest Discoveries & Emerging Trends in MDD" session New epidemiological research on risks associated with anxiety and depression plus five posters
- 2mo agoDFTXDefinium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 ResultsBusiness WireSecond FDA Breakthrough Therapy designation for DT120 reinforces its potential across MDD and generalized anxiety disorder (GAD), two disorders with significant unmet need Definium Therapeutics, Inc.
- 2mo agoDFTXDefinium Therapeutics Announces New Employee Inducement GrantsBusiness WireDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of
- 2mo agoDFTXDefinium Therapeutics to Participate at Upcoming Investor Conferences and EventsBusiness WireDefinium Therapeutics, Inc. (NASDAQ:DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes
- 2mo agoDFTXDefinium Therapeutics Announces New Employee Inducement GrantsBusiness WireDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of
- 3mo agoDFTXPhase 3 Voyage Topline Results: DT120 ODT in Generalized Anxiety Disorder - DEFINIUM THERAPEUTICS INCEarnings Call TranscriptsHello, and welcome to the Definium Therapeutics Phase 3 Voyage Topline Results Call. We ask that you please hold all questions until the end of the prepared remarks, at which time you will be given instructions for the q
- 3mo agoDFTXPhase 3 Voyage Topline Results: DT120 ODT in Generalized Anxiety Disorder - DEFINIUM THERAPEUTICS INCEarnings Call TranscriptsHello, and welcome to the Definium Therapeutics Phase 3 Voyage Topline Results Call. We ask that you please hold all questions until the end of the prepared remarks, at which time you will be given instructions for the q
- 3mo agoDFTXDefinium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety DisorderBusiness WireStudy met primary and all key secondary efficacy endpoints Participants receiving DT120 ODT achieved a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-A) score, with a placebo-adjusted
- 3mo agoDFTXQ2 2026 Earnings Call - DEFINIUM THERAPEUTICS INCEarnings Call TranscriptsGood afternoon. I am Gita Jane, Head of Investor Relations, and I want to thank you for joining us today for Definium Therapeutics' second quarter 2026 Financial Results and Recent Highlights conference call. All partici
- 3mo agoDFTXQ2 2026 Earnings Call - DEFINIUM THERAPEUTICS INCEarnings Call TranscriptsGood afternoon. I am Gita Jane, Head of Investor Relations, and I want to thank you for joining us today for Definium Therapeutics' second quarter 2026 Financial Results and Recent Highlights conference call. All partici
- 3mo agoDFTXDefinium Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsBusiness WireAnnounced positive topline results from Phase 3 Emerge study of DT120 ODT in major depressive disorder (MDD), demonstrating rapid, robust, and durable efficacy Topline results from Phase 3 GAD studies of DT120 ODT in
- 3mo agoHELPDFTXCMPSJNJ+1A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 ReadoutGlobeNewswireNEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - In biotech, the gap between a promising drug and a commercial success is often bridged by a single thing: the operator who has done it
- 3mo agoDFTXDefinium Therapeutics Announces New Employee Inducement GrantsBusiness WireDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of
- 3mo agoDFTXDefinium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026Business WireDefinium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders,
- 3mo agoHELPCMPSGHRSDFTX+1A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps WideningPR NewswireUSA News Group - News Commentary - Depression remains one of the most stubborn problems in modern medicine, and the numbers behind it are staggering. ...
- 3mo agoDFTXDefinium Therapeutics Announces New Employee Inducement GrantsBusiness WireDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of
- 3mo agoLLYDFTXCMPSHELP+4The market for psychedelic drugs to treat mental health conditions gets a big buy signalCNBCEli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.
- 3mo agoHELPLLYATAICMPS+2Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real TimePR NewswireFor half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE: LLY)...
- 3mo agoDFTXDefinium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and NeurobiologyBusiness WireGAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervasive, and debilitating symptoms1,2,3 Patients experience high rates of pharmacotherapy switching, discontinuation,
- 4mo agoDFTXNew Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)Business WireData highlight the challenges of achieving response and sustained remission in newly diagnosed and established GAD patients with existing therapies Definium Therapeutics, Inc. (NASDAQ:DFTX) ("Definium" or the
- 4mo agoDFTXDefinium Therapeutics Announces New Employee Inducement GrantsBusiness WireDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of
- 4mo agoHELPDFTXCMPSGHRS+1Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge OpportunityGlobeNewswireNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on
- 4mo agoHELPCMPSDFTXGHRSA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This YearPR NewswireUSA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a data...
- 4mo agoDFTXDefinium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public OfferingBusiness WireDefinium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes
- 4mo agoDFTXDefinium Therapeutics, Inc. Announces Proposed Public OfferingBusiness WireDefinium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes
- 4mo agoDFTXDefinium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive DisorderBusiness WireStudy met primary and all key secondary efficacy endpoints 8.1 point Montgomery-Åsberg Depression Rating Scale (MADRS) placebo-adjusted change from baseline at Week 6 for the primary endpoint (p<0.0001) 7.3
- 4mo agoDFTXDefinium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026Business WireCompany to host webcast tomorrow at 8:00 a.m. EDT Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics
- 5mo agoDFTXDefinium Therapeutics Announces New Employee Inducement GrantsBusiness WireDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and
- 5mo agoDFTXDefinium Therapeutics to Participate in the 2026 Jefferies Global Healthcare ConferenceBusiness WireDefinium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders,
- 6mo agoDFTXDefinium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive DisorderBusiness WireThe primary endpoint will measure the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between DT120 Orally Disintegrating Tablet (ODT) 100 µg and placebo Ascend builds on
- 6mo agoDFTXDefinium Therapeutics Announces New Employee Inducement GrantsBusiness WireDefinium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and
- 6mo agoDFTXDefinium Therapeutics Q1 2026 Earnings Conference CallDEFINIUM THERAPEUTICS INCEarnings Call TranscriptsGood afternoon. I am Gita Jain, Head of Investor Relations, and thank you for joining us today for Definium Therapeutics' first quarter 2026 Financial Results and Recent Highlights conference call. Currently, all partici
- 6mo agoDFTXDefinium Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsBusiness WireThree Phase 3 topline data readouts for DT120 ODT expected in the coming months DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in 2027 $373.4 million in cash, cash equivalents,
- 6mo agoDFTXDefinium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026Business WireDefinium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders,
- 6mo agoDFTXDefinium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst DayBusiness WireMDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing anticipated in 2Q 2026 GAD: Voyage enrollment complete with 214 patients with topline data readout on track